Fulminant hepatitis following bone marrow transplantation in hepatitis B virus carrier siblings.

Abstract

A 19-year-old male healthy hepatitis B virus (HBV) carrier developed fulminant hepatitis following allogenic bone marrow transplantation (BMT) from his brother, who was also a healthy HBV carrier, during the first complete remission of acute myelogenic leukemia (M1, FAB classification). Serum markers related to both HBV and hepatitis C virus (HCV) were elevated during active liver injury when a point mutation in the precore (pre-C) region occurred in the HBV. The patient received low-dose interferon alpha (IFN-alpha), while the dose of cyclosporin A was tapered; the patient eventually recovered from the liver injury. Fulminant hepatitis due to HBV and/or HCV following BMT is rare, and it is considered to have a very poor prognosis. The rationale for the use of low-dose IFN-alpha with cyclosporin A (CyA) is discussed.

• Authors: F Omata, F Ueno, Y Kushibiki, H Takahashi
• Journal: Journal of gastroenterology (J Gastroenterol) Vol. 29 Issue 5 Pg. 653-5 (Oct 1994) ISSN: 0944-1174 [Print] Japan
• PMID: 8000516 (Publication Type: Case Reports, Journal Article)

Chemical References

• Interferon-alpha
• Cyclosporine

Topics

• Adult
• Bone Marrow Transplantation (adverse effects)
• Carrier State
• Cyclosporine (administration & dosage, adverse effects)
• Hepatitis B (complications)
• Hepatitis C
• Humans
• Interferon-alpha (administration & dosage)
• Leukemia, Myeloid, Acute (therapy)
• Male